Skip to main content
Premium Trial:

Request an Annual Quote

The Economics of Personalized Medicine

The Wall Street Journal's Hester Plumridge writes that personalized medicine offers advantages, but also poses challenges for pharmaceutical companies. Giving patients a drug that is known to be effective for their genetic profile not only will lower health care costs and limit adverse reactions, but also, Plumridge says, minimize the number of liability claims filed against pharma companies. The problem, though, is that personalizing medicine will narrow each drug's market, leading to lower sales, but he notes that in a limited market, pharma companies could then charge a higher price.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.